How progestins influence the cardiovascular effect of hormone replacement therapy

G. M C Rosano, G. Mercuro, C. Vitale, P. Rossini, P. Galetta, M. Fini

Research output: Contribution to journalArticlepeer-review


Hormone replacement therapy aims to protect against osteoporosis and alleviate fastidious menopausal symptoms such as hot flushes, depression, sleep disturbances and vaginal dryness. In view of the acknowledgement of estrogen deficiency as a major trigger for the acceleration of cardiovascular risk after menopause, hormone replacement therapy may also be proposed as a substantial beneficial cardioprotective agent. The effects of progestins on lipoprotein profile and vasomotor tone are dependent on the chemical structure and the scheme of administration of progestins, with androgenic progestins and cyclical therapy having a potential detrimental effect. Prospective primary and secondary prevention studies, however, suggest that the adjunct of non-androgenic progestins to estrogen therapy is at least as effective as estrogen replacement therapy in reducing cardiovascular mortality and morbidity. Data from recent randomized secondary prevention studies have to be viewed with caution.

Original languageEnglish
Pages (from-to)9-17
Number of pages9
JournalGynecological Endocrinology
Issue numberSUPPL. 6
Publication statusPublished - 2001


  • Cardiovascular effects
  • Hormone replacement therapy
  • Progestins

ASJC Scopus subject areas

  • Endocrinology
  • Obstetrics and Gynaecology


Dive into the research topics of 'How progestins influence the cardiovascular effect of hormone replacement therapy'. Together they form a unique fingerprint.

Cite this